biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > sent a pm to kbc this morning - no response

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 21, 2022 4:52pm

96 Views

Post# 35185766

RE:RE:RE:RE:sent a pm to kbc this morning - no response

KayackerBC references a post from way back in 2017 and says, "Look at the title on the first one. Is that not true today?"

Title: "Now there's a great big opinion being expressed in the market!"

He can't see a difference with the current moment...
What's the big opinion being expressed right now?

Ladenberg Thalmann, a company with US$125 billion in assets under management according to Wikepedia, has just put together a deal where Armistice Capital is the sole placee in support of a NASDAQ listing. Saltarelli is excited after 2 1/2 years on the Chiesi Advisory Board with Rathjen and Hunter has been nominated lead xB3 asset. The cash needs of the company are about to be addressed as never before with US$20 million in potential cash. J&J is working on xB3 and Q-Sphera. Midatech, with valuable clinical stage assets of its own, has agreed to a merger. There is so much of note that is different in this moment but I've already gone over it already. There is a big opinion being expressed that this moment is different.

Armistice Capital:

Portfolio value: $5.765 billion
Number of posiitions: 197

The portfolio has done very well in terms of value:

Armistice Capital, Llc - Portfolio Value

Armistice Capital, Llc - Portfolio Value

@HedgeMind

Steven Boyd's Armistice Capital is a long/short, value-oriented and event-driven hedge funds. Armistice is one of the best event-driven biotech focused funds we know, though it is hard for us to quantify its overall performance due to the very nature of its investing strategy.